| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A century of pneumococcal vaccination research in humans
|
Grabenstein, J.D.
|
|
2012
|
|
S5 |
p. 15-24
10 p.
|
artikel
|
| 2 |
A cohesive European policy for hepatitis B vaccination, are we there yet?
|
Lernout, T.
|
|
2014
|
|
S5 |
p. 19-24
6 p.
|
artikel
|
| 3 |
Actual immunization coverage throughout Europe: are existing data sufficient?
|
Lopalco, P.L.
|
|
2014
|
|
S5 |
p. 7-11
5 p.
|
artikel
|
| 4 |
Advances in the management of pneumonia in the intensive care unit: review of current thinking
|
Rello, J.
|
|
2005
|
|
S5 |
p. 30-38
9 p.
|
artikel
|
| 5 |
An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients
|
Glasmacher, A.
|
|
2005
|
|
S5 |
p. 17-23
7 p.
|
artikel
|
| 6 |
Antibiotic resistance: learning from animal feeds and animal experimentation
|
Moreillon, P.
|
|
2001
|
|
S5 |
p. 13-18
6 p.
|
artikel
|
| 7 |
A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for haemorrhagic fever with renal syndrome delivered by intramuscular electroporation
|
Hooper, J.W.
|
|
2014
|
|
S5 |
p. 110-117
8 p.
|
artikel
|
| 8 |
Barriers to the vaccination of children and adolescents and possible solutions
|
Esposito, S.
|
|
2014
|
|
S5 |
p. 25-31
7 p.
|
artikel
|
| 9 |
B cell and T cell immunity in the female genital tract: Potential of distinct mucosal routes of vaccination and role of tissue-associated dendritic cells and natural killer cells
|
Anjuère, F.
|
|
2012
|
|
S5 |
p. 117-122
6 p.
|
artikel
|
| 10 |
Can infants be protected by means of maternal vaccination?
|
Esposito, S.
|
|
2012
|
|
S5 |
p. 85-92
8 p.
|
artikel
|
| 11 |
Can we control all-cause meningococcal disease in Europe?
|
Sadarangani, M.
|
|
2016
|
|
S5 |
p. S103-S112
10 p.
|
artikel
|
| 12 |
Changing epidemiology of an emerging infection: zygomycosis
|
Meis, J.F.
|
|
2009
|
|
S5 |
p. 10-14
5 p.
|
artikel
|
| 13 |
Clinical presentation of zygomycosis
|
Mantadakis, E.
|
|
2009
|
|
S5 |
p. 15-20
6 p.
|
artikel
|
| 14 |
Compliance with anti-H1N1 vaccine among healthcare workers and general population
|
Blasi, F.
|
|
2012
|
|
S5 |
p. 37-41
5 p.
|
artikel
|
| 15 |
Critical research concepts in tuberculosis vaccine development
|
Delogu, G.
|
|
2014
|
|
S5 |
p. 59-65
7 p.
|
artikel
|
| 16 |
Current experience in treating invasive zygomycosis with posaconazole
|
Cornely, O.A.
|
|
2009
|
|
S5 |
p. 77-81
5 p.
|
artikel
|
| 17 |
Cutaneous zygomycosis
|
Skiada, A.
|
|
2009
|
|
S5 |
p. 41-45
5 p.
|
artikel
|
| 18 |
Cytomegalovirus vaccine: phase II clinical trial results
|
Rieder, F.
|
|
2014
|
|
S5 |
p. 95-102
8 p.
|
artikel
|
| 19 |
Developing vaccines in the era of genomics: a decade of reverse vaccinology
|
Seib, K.L.
|
|
2012
|
|
S5 |
p. 109-116
8 p.
|
artikel
|
| 20 |
Disseminated zygomycosis with involvement of the central nervous system
|
Skiada, A.
|
|
2009
|
|
S5 |
p. 46-49
4 p.
|
artikel
|
| 21 |
Economic evaluation of vaccination: capturing the full benefits, with an application to human papillomavirus
|
Bärnighausen, T.
|
|
2012
|
|
S5 |
p. 70-76
7 p.
|
artikel
|
| 22 |
Erratum concerning Volume 14, Supplement 1, January 2008
|
|
|
2008
|
|
S5 |
p. 21-24
4 p.
|
artikel
|
| 23 |
European expert opinion on the management of invasive candidiasis in adults
|
Kullberg, B.J.
|
|
2011
|
|
S5 |
p. 1-12
12 p.
|
artikel
|
| 24 |
Evaluating and predicting the ecologic impact of antibiotics
|
Andremont, A.
|
|
2001
|
|
S5 |
p. 1-6
6 p.
|
artikel
|
| 25 |
Foreword
|
Schlemmer, B.
|
|
2001
|
|
S5 |
p. iii-
1 p.
|
artikel
|
| 26 |
Hexavalent vaccines for immunization in paediatric age
|
Esposito, S.
|
|
2014
|
|
S5 |
p. 76-85
10 p.
|
artikel
|
| 27 |
How can we predict the ecologic impact of an antimicrobial: the opinions of a population and evolutionary biologist
|
Levin, B.R.
|
|
2001
|
|
S5 |
p. 24-28
5 p.
|
artikel
|
| 28 |
How to evaluate and predict the ecologic impact of antibiotics: a regulatory view
|
Simonian, S.
|
|
2001
|
|
S5 |
p. 49-51
3 p.
|
artikel
|
| 29 |
How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development
|
Bax, R.
|
|
2001
|
|
S5 |
p. 46-48
3 p.
|
artikel
|
| 30 |
How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach
|
Guillemot, D.
|
|
2001
|
|
S5 |
p. 19-23
5 p.
|
artikel
|
| 31 |
How to evaluate the ecologic impact of antibiotics in phase III trials
|
Carbon, C.
|
|
2001
|
|
S5 |
p. 42-45
4 p.
|
artikel
|
| 32 |
Hyperbaric oxygen therapy and other adjunctive treatments for zygomycosis
|
Tragiannidis, A.
|
|
2009
|
|
S5 |
p. 82-86
5 p.
|
artikel
|
| 33 |
Immunization against pertussis in adolescents and adults
|
Esposito, S.
|
|
2016
|
|
S5 |
p. S89-S95
7 p.
|
artikel
|
| 34 |
Impact of antibiotic restrictions: the ethical perspective
|
Garau, J.
|
|
2006
|
|
S5 |
p. 16-24
9 p.
|
artikel
|
| 35 |
Impact of antibiotic restrictions: the patient's perspective
|
Wagstaff, B.
|
|
2006
|
|
S5 |
p. 10-15
6 p.
|
artikel
|
| 36 |
Impact of antibiotic restrictions: the pharmaceutical perspective
|
Power, E.
|
|
2006
|
|
S5 |
p. 25-34
10 p.
|
artikel
|
| 37 |
Impact of antibiotic restrictions: the physician's perspective
|
Price, D.
|
|
2006
|
|
S5 |
p. 3-9
7 p.
|
artikel
|
| 38 |
Incidence of zygomycosis in transplant recipients
|
Cuenca-Estrella, M.
|
|
2009
|
|
S5 |
p. 37-40
4 p.
|
artikel
|
| 39 |
Infection control measures to limit the spread of Clostridium difficile
|
Vonberg, R.-P.
|
|
2008
|
|
S5 |
p. 2-20
19 p.
|
artikel
|
| 40 |
Introduction
|
Riley, T.V.
|
|
2008
|
|
S5 |
p. 1-
1 p.
|
artikel
|
| 41 |
Introduction
|
Finch, R.
|
|
2006
|
|
S5 |
p. 1-2
2 p.
|
artikel
|
| 42 |
Introduction to the supplement on ‘Vaccines for mutual protection’
|
Gyssens, I.C.
|
|
2016
|
|
S5 |
p. S83-S84
2 p.
|
artikel
|
| 43 |
Invasive zygomycosis in neonates and children
|
Roilides, E.
|
|
2009
|
|
S5 |
p. 50-54
5 p.
|
artikel
|
| 44 |
In vitro activity of antifungals against Zygomycetes
|
Alastruey-Izquierdo, A.
|
|
2009
|
|
S5 |
p. 71-76
6 p.
|
artikel
|
| 45 |
In vitro selection of antibiotic resistance in Pseudomonas aeruginosa
|
Köhler, T.
|
|
2001
|
|
S5 |
p. 7-10
4 p.
|
artikel
|
| 46 |
Lifelong vaccination as a key disease-prevention strategy
|
Bonanni, P.
|
|
2014
|
|
S5 |
p. 32-36
5 p.
|
artikel
|
| 47 |
Lipid formulations of amphotericin B as first-line treatment of zygomycosis
|
Petrikkos, G.L.
|
|
2009
|
|
S5 |
p. 87-92
6 p.
|
artikel
|
| 48 |
Live pertussis vaccines: will they protect against carriage and spread of pertussis?
|
Locht, C.
|
|
2016
|
|
S5 |
p. S96-S102
7 p.
|
artikel
|
| 49 |
Louis Pasteur, from crystals of life to vaccination
|
Berche, P.
|
|
2012
|
|
S5 |
p. 1-6
6 p.
|
artikel
|
| 50 |
Making sense of antimicrobial use and resistance surveillance data: application of ARIMA and transfer function models
|
Monnet, D.L.
|
|
2001
|
|
S5 |
p. 29-36
8 p.
|
artikel
|
| 51 |
Management of the febrile neutropenic cancer patient: lessons from 40 years of study
|
Bow, E.J.
|
|
2005
|
|
S5 |
p. 24-29
6 p.
|
artikel
|
| 52 |
Managing serious infections in the hospital: a new model
|
Baughman, R.P.
|
|
2005
|
|
S5 |
p. 1-3
3 p.
|
artikel
|
| 53 |
Measles still spreads in Europe: who is responsible for the failure to vaccinate?
|
Carrillo-Santisteve, P.
|
|
2012
|
|
S5 |
p. 50-56
7 p.
|
artikel
|
| 54 |
Molecular tools for identification of Zygomycetes and the diagnosis of zygomycosis
|
Dannaoui, E.
|
|
2009
|
|
S5 |
p. 66-70
5 p.
|
artikel
|
| 55 |
Orbitomaxillary mucormycosis (zygomycosis) and the surgical approach to treatment: perspectives from a maxillofacial surgeon
|
Rapidis, A.D.
|
|
2009
|
|
S5 |
p. 98-102
5 p.
|
artikel
|
| 56 |
Outbreaks of zygomycosis in hospitals
|
Antoniadou, A.
|
|
2009
|
|
S5 |
p. 55-59
5 p.
|
artikel
|
| 57 |
Outlook for a dengue vaccine
|
Norrby, R.
|
|
2014
|
|
S5 |
p. 92-94
3 p.
|
artikel
|
| 58 |
Pneumococcal infection in adults: burden of disease
|
Drijkoningen, J.J.C.
|
|
2014
|
|
S5 |
p. 45-51
7 p.
|
artikel
|
| 59 |
Pneumococcal vaccines for children: a global public health priority
|
Pittet, L.F.
|
|
2012
|
|
S5 |
p. 25-36
12 p.
|
artikel
|
| 60 |
Potential safety issues and other factors that may affect the introduction and uptake of rotavirus vaccines
|
Aliabadi, N.
|
|
2016
|
|
S5 |
p. S128-S135
8 p.
|
artikel
|
| 61 |
Preventing influenza in younger children
|
Esposito, S.
|
|
2012
|
|
S5 |
p. 42-49
8 p.
|
artikel
|
| 62 |
Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges
|
Poljak, M.
|
|
2012
|
|
S5 |
p. 64-69
6 p.
|
artikel
|
| 63 |
Public health response to the silent reintroduction of wild poliovirus to Israel, 2013–2014
|
Moran-Gilad, J.
|
|
2016
|
|
S5 |
p. S140-S145
6 p.
|
artikel
|
| 64 |
Role of vaccine manufacturers in developing countries towards global healthcare by providing quality vaccines at affordable prices
|
Jadhav, S.
|
|
2014
|
|
S5 |
p. 37-44
8 p.
|
artikel
|
| 65 |
Rotavirus vaccination: a concise review
|
Vesikari, T.
|
|
2012
|
|
S5 |
p. 57-63
7 p.
|
artikel
|
| 66 |
Seasonal influenza vaccines and hurdles to mutual protection
|
Chiu, C.
|
|
2016
|
|
S5 |
p. S113-S119
7 p.
|
artikel
|
| 67 |
Squeezing the antibiotic balloon: the impact of antimicrobial classes on emerging resistance
|
Peterson, L.R.
|
|
2005
|
|
S5 |
p. 4-16
13 p.
|
artikel
|
| 68 |
1st International Forum on Zygomycosis, 30 May to 1 June 2008
|
Petrikkos, G.
|
|
2009
|
|
S5 |
p. 1-
1 p.
|
artikel
|
| 69 |
The contribution of in vitro bacteriologic experiments
|
Varon, E.
|
|
2001
|
|
S5 |
p. 11-12
2 p.
|
artikel
|
| 70 |
The ecology of the Zygomycetes and its impact on environmental exposure
|
Richardson, M.
|
|
2009
|
|
S5 |
p. 2-9
8 p.
|
artikel
|
| 71 |
The evaluation and prediction of the ecologic impact of antibiotics in human phase I and II trials
|
Edlund, C.
|
|
2001
|
|
S5 |
p. 37-41
5 p.
|
artikel
|
| 72 |
The impact of vaccines on public health: the role of ESCMID
|
Poljak, M.
|
|
2014
|
|
S5 |
p. 1-
1 p.
|
artikel
|
| 73 |
The importance of the patient voice in vaccination and vaccine safety—are we listening?
|
Holt, D.
|
|
2016
|
|
S5 |
p. S146-S153
8 p.
|
artikel
|
| 74 |
The role of iron and iron chelators in zygomycosis
|
Symeonidis, A.S.
|
|
2009
|
|
S5 |
p. 26-32
7 p.
|
artikel
|
| 75 |
The role of neutrophils in the development and outcome of zygomycosis in haematological patients
|
Pagano, L.
|
|
2009
|
|
S5 |
p. 33-36
4 p.
|
artikel
|
| 76 |
The role of surveillance in assuring mutual protection for vaccine-preventable diseases
|
Lopalco, P.L.
|
|
2016
|
|
S5 |
p. S85-S88
4 p.
|
artikel
|
| 77 |
The role of vaccination in preventing pneumococcal disease in adults
|
Aliberti, S.
|
|
2014
|
|
S5 |
p. 52-58
7 p.
|
artikel
|
| 78 |
The spread of vaccine-preventable diseases by international travellers: a public-health concern
|
Gautret, P.
|
|
2012
|
|
S5 |
p. 77-84
8 p.
|
artikel
|
| 79 |
The state of measles and rubella in the WHO European Region, 2013
|
Muscat, M.
|
|
2014
|
|
S5 |
p. 12-18
7 p.
|
artikel
|
| 80 |
Understanding the burden of pneumococcal disease in adults
|
Blasi, F.
|
|
2012
|
|
S5 |
p. 7-14
8 p.
|
artikel
|
| 81 |
Universal influenza vaccines: a realistic option?
|
de Vries, R.D.
|
|
2016
|
|
S5 |
p. S120-S124
5 p.
|
artikel
|
| 82 |
Vaccination of immunocompromised patients
|
Ljungman, Per
|
|
2012
|
|
S5 |
p. 93-99
7 p.
|
artikel
|
| 83 |
Vaccine-preventable diseases: the role of the European Centre for Disease Prevention and Control
|
Kramarz, P.
|
|
2014
|
|
S5 |
p. 2-6
5 p.
|
artikel
|
| 84 |
Vaccines against human papillomavirus infections: protection against cancer, genital warts or both?
|
Joura, E.A.
|
|
2016
|
|
S5 |
p. S125-S127
3 p.
|
artikel
|
| 85 |
Vaccines against norovirus: state of the art trials in children and adults
|
Baehner, F.
|
|
2016
|
|
S5 |
p. S136-S139
4 p.
|
artikel
|
| 86 |
Vaccines for the elderly
|
Weinberger, B.
|
|
2012
|
|
S5 |
p. 100-108
9 p.
|
artikel
|
| 87 |
Varicella vaccination: a laboured take-off
|
Carrillo-Santisteve, P.
|
|
2014
|
|
S5 |
p. 86-91
6 p.
|
artikel
|
| 88 |
Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices?
|
Pongas, G.N.
|
|
2009
|
|
S5 |
p. 93-97
5 p.
|
artikel
|
| 89 |
Where does a Staphylococcus aureus vaccine stand?
|
Fowler Jr, V.G.
|
|
2014
|
|
S5 |
p. 66-75
10 p.
|
artikel
|
| 90 |
Why is it so difficult to develop a hepatitis C virus preventive vaccine?
|
Zingaretti, C.
|
|
2014
|
|
S5 |
p. 103-109
7 p.
|
artikel
|
| 91 |
Zygomycosis and diabetes mellitus
|
Lanternier, F.
|
|
2009
|
|
S5 |
p. 21-25
5 p.
|
artikel
|
| 92 |
Zygomycosis: conventional laboratory diagnosis
|
Lass-Flörl, C.
|
|
2009
|
|
S5 |
p. 60-65
6 p.
|
artikel
|
Tijdschrift beschrijving